WEBSITE BSE:0 NSE: Inc. Year: 2006 Industry: Pesticides & Agrochemicals My Bucket: Add Stock
Last updated: 15:31
No Notes Added Yet
Crop Life Science Ltd. began as a small-scale unit nearly two decades ago, manufacturing crop protection chemicals. Today, it stands as one of leading manufacturers of a wide range of products including insecticides, fungicides, herbicides, plant growth regulators, and soil plant health products. Company’s manufacturing units are located at Ankleshwar in Gujarat operating with world-class technologies and quality services. Crop Life Science Ltd. is certified with International Standard ISO 9001:2015 and ISO 14001:2004 for quality assura...Read More
Crop Life Science Ltd. began as a small-scale unit nearly two decades ago, manufacturing crop protection chemicals. Today, it stands as one of leading manufacturers of a wide range of products including insecticides, fungicides, herbicides, plant growth regulators, and soil plant health products. Company’s manufacturing units are located at Ankleshwar in Gujarat operating with world-class technologies and quality services. Crop Life Science Ltd. is certified with International Standard ISO 9001:2015 and ISO 14001:2004 for quality assurance. R&D is a major strength and company continues to invest in innovative formulations that are environmentally and user-friendly. The aim of Crop Life Science Ltd. is to build strong relationships with customers understand their needs and deliver real performance in terms of usage. The company helps in improving life for the world’s population by supplying quality products that assist farmers in increasing yields. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹75 Cr.
Stock P/E 13.3
P/B 1
Current Price ₹43.5
Book Value ₹ 45.2
Face Value 10
52W High ₹62.8
Dividend Yield 0%
52W Low ₹ 39.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Net Sales | 131 | 199 | 201 | |
| Other Income | 1 | 2 | 2 | |
| Total Income | 132 | 201 | 202 | |
| Total Expenditure | 119 | 186 | 185 | |
| Operating Profit | 13 | 15 | 17 | |
| Interest | 3 | 3 | 5 | |
| Depreciation | 4 | 3 | 5 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | |
| Profit Before Tax | 6 | 8 | 8 | |
| Provision for Tax | 2 | 2 | 2 | |
| Profit After Tax | 4 | 6 | 6 | |
| Adjustments | 0 | 0 | 0 | |
| Profit After Adjustments | 4 | 6 | 6 | |
| Adjusted Earnings Per Share | 3.4 | 3.5 | 3.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 1% | 0% | 0% | 0% |
| Operating Profit CAGR | 13% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -11% | NA% | NA% | NA% |
| ROE Average | 8% | 9% | 9% | 9% |
| ROCE Average | 11% | 13% | 13% | 13% |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Shareholder's Funds | 41 | 72 | 77 |
| Minority's Interest | 0 | 4 | 4 |
| Borrowings | 6 | 6 | 3 |
| Other Non-Current Liabilities | 1 | 5 | 5 |
| Total Current Liabilities | 56 | 95 | 95 |
| Total Liabilities | 103 | 182 | 184 |
| Fixed Assets | 16 | 39 | 38 |
| Other Non-Current Assets | 0 | 1 | 2 |
| Total Current Assets | 87 | 142 | 144 |
| Total Assets | 103 | 182 | 184 |
| #(Fig in Cr.) | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 1 | 2 |
| Cash Flow from Operating Activities | 2 | -8 | -2 |
| Cash Flow from Investing Activities | -4 | -3 | -4 |
| Cash Flow from Financing Activities | 1 | 13 | 4 |
| Net Cash Inflow / Outflow | -2 | 2 | -1 |
| Closing Cash & Cash Equivalent | 0 | 2 | 1 |
| # | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Earnings Per Share (Rs) | 3.39 | 3.51 | 3.44 |
| CEPS(Rs) | 6.48 | 5.39 | 6.08 |
| DPS(Rs) | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 33.8 | 41.85 | 45.19 |
| Core EBITDA Margin(%) | 8.97 | 6.35 | 7.75 |
| EBIT Margin(%) | 6.76 | 5.79 | 6.26 |
| Pre Tax Margin(%) | 4.27 | 4.08 | 3.89 |
| PAT Margin (%) | 3.1 | 3.03 | 2.79 |
| Cash Profit Margin (%) | 5.93 | 4.65 | 5.2 |
| ROA(%) | 3.95 | 4.22 | 3.06 |
| ROE(%) | 10.04 | 10.72 | 7.51 |
| ROCE(%) | 13.33 | 13.56 | 11.35 |
| Receivable days | 90.55 | 100.91 | 133.34 |
| Inventory Days | 72.84 | 60.65 | 80.71 |
| Payable days | 79.13 | 90.76 | 121.49 |
| PER(x) | 0 | 10.47 | 14.84 |
| Price/Book(x) | 0 | 0.88 | 1.13 |
| Dividend Yield(%) | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.29 | 0.46 | 0.63 |
| EV/Core EBITDA(x) | 2.99 | 6.24 | 7.31 |
| Net Sales Growth(%) | 0 | 51.35 | 1 |
| EBIT Growth(%) | 0 | 29.63 | 9.12 |
| PAT Growth(%) | 0 | 47.77 | -6.9 |
| EPS Growth(%) | 0 | 3.58 | -2.19 |
| Debt/Equity(x) | 0.64 | 0.44 | 0.52 |
| Current Ratio(x) | 1.55 | 1.5 | 1.52 |
| Quick Ratio(x) | 1.08 | 1.08 | 1 |
| Interest Cover(x) | 2.71 | 3.39 | 2.64 |
| Total Debt/Mcap(x) | 0 | 0.5 | 0.46 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 70.01 | 70.01 | 70.01 | 70.01 | 70.01 | 70.01 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 29.99 | 29.99 | 29.99 | 29.99 | 29.99 | 29.99 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoter | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.71 | 1.71 | 1.71 | 1.71 | 1.71 | 1.71 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
